Turbinate Mesenchymal Stem Cell Differentiation for Regenerative Medicine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tissue engineering, such as organ and tissue transplantation, face limitations in regenerating cartilage, bone, and nerve tissues due to donor site defects, immune rejection, and the lack of active cells in biomaterials, necessitating the development of alternative cell sources with multipotency for therapeutic applications.
Innovation Solution
The method involves differentiating human turbinate mesenchymal stromal cells into cartilage, bone, and nerve cells using specific growth factors and culture mediums, including TGF-β1, IGF-I, GDNF, and BDNF, to create cells that can be used for treating injuries and diseases, and isolating mesenchymal stromal cells from human inferior turbinate tissues for use in regenerative medicine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autograft transplantation is used to reconstruct bone tissue, then the biological activity and regeneration capability are improved, but donor site defects and limited availability occur
Solution Approach 1:
The patient's own mesenchymal stromal cells are harvested, expanded in culture, and retransplanted to regenerate bone tissue at the defect site. This self-service approach eliminates the need for additional donor sites while maintaining full biological compatibility and regenerative capability.
Solution Approach 2:
The patent changes the physical and biological parameters of the cell population by expanding mesenchymal stromal cells in vitro from a small initial sample to a large sufficient quantity for transplantation, thereby resolving the contradiction between limited donor availability and sufficient transplant material.
2Quantity of substance
If allograft transplantation is used to obtain bone graft, then donor site limitations are avoided, but immune rejection and disease transmission risks increase
Solution Approach 1:
The patient receives their own autologous mesenchymal stromal cells that have been expanded in culture, eliminating immune rejection and disease transmission risks associated with allogeneic transplantation while still providing sufficient cell quantity for effective bone regeneration.
3Reliability
If osteoblast is used as cell source for bone tissue reconstruction, then direct bone formation capability is improved, but proliferation ability in vitro is reduced
Solution Approach 1:
Mesenchymal stromal cells are preliminarily expanded in vitro to achieve sufficient cell numbers before inducing differentiation into osteoblasts. This preliminary expansion resolves the contradiction by obtaining adequate cell quantity before the differentiation stage where proliferation capability is naturally reduced.
Solution Approach 2:
The patent dynamically controls the differentiation process by adjusting culture conditions and growth factors at different stages, allowing cells to first proliferate as undifferentiated mesenchymal stromal cells and then differentiate into osteoblasts when sufficient numbers are achieved, thereby optimizing both productivity and reliability.
4Reliability
If cartilage cells are cultured to reconstruct damaged cartilage, then cartilage regeneration capability is improved, but donor site complications increase
Solution Approach 1:
Mesenchymal stromal cells are harvested from the patient's own adipose tissue or bone marrow and differentiated into cartilage cells in vitro, eliminating the need for additional cartilage donor sites and avoiding associated complications while maintaining effective cartilage regeneration capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the effective differentiation of human turbinate mesenchymal stromal cells into various cell types, providing a viable source for cell replacement therapy and regenerative medicine, overcoming the limitations of existing tissue engineering techniques by utilizing easily obtainable cells from discarded tissues during surgical procedures.
Implementation Method 1
a cartilage cell differentiation medium including transforming growth factor-β1 (TGF-β1) or insulin like growth factor-I (IGF-I)
Implementation Method 2
a nerve cell differentiation medium including a glial-derived neurotrophin factor (GDNF), a brain-derived neurotrophin factor (BDNF), or a neurotrophin-3 (NT3)
Data Source
Figure 1~3C
Figure 4A~6
Figure 7~8D
AI summary
The present invention relates to a method for inducing differentiation of human inferior turbinate mesenchymal stromal cells to bone cells, cartilage cells or nerve cells. More particularly, the present invention relates to a method for inducing differentiation of human inferior turbinate mesenchymal stromal cells to bone cells, cartilage cells, nerve cells or fat cells, wherein the method comprises the step of culturing the mesenchymal stromal cells that are isolated from human inferior turbinate tissues in a medium containing growth factors. The present invention also relates to a composition for prevention or treatment of cartilage injury or disease, bone injury or osseous metabolic disease, or nerve injury or disease that contain cells differentiated by said method as active ingredients. The bone cells, cartilage cells, nerve cells or fat cells differentiated from human inferior turbinate mesenchymal stromal cells according to the present invention can be used in the fields of cell replacement therapy and regenerative medicine for treating diseases caused by the damage of said cells, and the human inferior turbinate tissues used in the present invention can be easily obtained as the source of the cells from the discarded tissues during inferior turbinate surgery.